tiprankstipranks
In this article:
Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Global Blood Therapeutics (GBTResearch Report), Verona Pharma (VRNAResearch Report) and Stealth Biotherapeutics (MITOResearch Report) with bullish sentiments.

Global Blood Therapeutics (GBT)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Global Blood Therapeutics, with a price target of $65.00. The company’s shares closed last Wednesday at $24.42, close to its 52-week low of $22.67.

According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -18.6% and a 30.0% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals.

Global Blood Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $61.29.

See today’s best-performing stocks on TipRanks >>

Verona Pharma (VRNA)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Verona Pharma today and set a price target of $25.00. The company’s shares closed last Wednesday at $4.99.

According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -40.3% and a 13.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Aquestive Therapeutics, and Oramed Pharmaceuticals.

Verona Pharma has an analyst consensus of Strong Buy, with a price target consensus of $25.00.

Stealth Biotherapeutics (MITO)

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Stealth Biotherapeutics, with a price target of $1.50. The company’s shares closed last Wednesday at $0.33, close to its 52-week low of $0.16.

According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -8.5% and a 33.6% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Stealth Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $1.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on GBT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed